Evidence map›Paper›PMID 37988640›Full record

ArticleJCO clinical cancer informatics2023

Comparing Active Surveillance and Watchful Waiting With Radical Treatment Using Machine Learning Models Among Patients With Prostate Cancer.

Siqi Hu, Chun-Pin Chang, John Snyder, Vikrant Deshmukh, Michael Newman, Ankita Date, Carlos Galvao, Christina A Porucznik, Lisa H Gren, Alejandro Sanchez and 4 more

Open access · greenAbstract read
In one paragraph

Article in JCO clinical cancer informatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Siqi HuHuntsman Cancer Institute, Salt Lake City, UT.
Chun-Pin ChangHuntsman Cancer Institute, Salt Lake City, UT.ORCID 0000-0002-0878-997X
John SnyderIntermountain Healthcare, Salt Lake City, UT.ORCID 0009-0001-1504-145X
Vikrant DeshmukhUniversity of Utah Health Sciences Center, Salt Lake City, UT.ORCID 0000-0001-6670-8245
Michael NewmanUniversity of Utah Health Sciences Center, Salt Lake City, UT.ORCID 0000-0002-3147-6058
Ankita DatePedigree and Population Resource, Population Sciences, Huntsman Cancer Institute, Salt Lake City, UT.ORCID 0000-0002-1792-9436
Carlos GalvaoPedigree and Population Resource, Population Sciences, Huntsman Cancer Institute, Salt Lake City, UT.
Christina A PorucznikDivision of Public Health, Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT.ORCID 0000-0003-1973-2917
Lisa H GrenDivision of Public Health, Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT.ORCID 0000-0002-5868-3292
Alejandro SanchezDivision of Urology, Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT.
Shane LloydDepartment of Radiation Oncology, University of Utah School of Medicine, Salt Lake City, UT.
Benjamin HaalandHuntsman Cancer Institute, Salt Lake City, UT.
Brock O'NeilDivision of Urology, Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT.ORCID 0000-0002-1497-5824
Mia HashibeHuntsman Cancer Institute, Salt Lake City, UT.ORCID 0000-0002-6903-2049
University of Utah · USHuntsman Cancer Institute · USIntermountain Healthcare · US

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6M
Long-Term Adverse Outcomes Among Rural Cancer Survivors in a Population-Based CohortR01CA244326 · NCI · UNIVERSITY OF UTAH · PI CAMP, NICOLA J., HASHIBE, MIA · 2020 to 2024
$2.4M
Population-based Cohort of Endometrial Cancer Survivors in UtahR21CA185811 · NCI · UNIVERSITY OF UTAH · PI HASHIBE, MIA · 2015 to 2016
$356k
Epidemiology of testicular cancer in the Utah populationR03CA159357 · NCI · UNIVERSITY OF UTAH · PI HASHIBE, MIA · 2011 to 2012
$150k
NCI NIH HHS HHSN261201800016CNCI NIH HHS HHSN261201800016INCI NIH HHS P30 CA042014NCI NIH HHS R01 CA244326NCI NIH HHS R03 CA159357NCI NIH HHS R21 CA185811
6 · The paper itself

Abstract

purposeIn 2021, 59.6% of low-risk patients with prostate cancer were under active surveillance (AS) as their first course of treatment. However, few studies have investigated AS and watchful waiting (WW) separately. The objectives of this study were to develop and validate a population-level machine learning model for distinguishing AS and WW in the conservative treatment group, and to investigate initial cancer management trends from 2004 to 2017 and the risk of chronic diseases among patients with prostate cancer with different treatment modalities.

methodsIn a cohort of 18,134 patients with prostate adenocarcinoma diagnosed between 2004 and 2017, 1,926 patients with available AS/WW information were analyzed using machine learning algorithms with 10-fold cross-validation. Models were evaluated using performance metrics and Brier score. Cox proportional hazard models were used to estimate hazard ratios for chronic disease risk.

resultsLogistic regression models achieved a test area under the receiver operating curve of 0.73,

conclusionA machine learning approach accurately distinguished AS and WW groups in conservative treatment in this decision analytical model study. Our results provide insight into the necessity to separate AS and WW in population-based studies.

Indexed as

Prostatic NeoplasmsWatchful WaitingHumansLogistic ModelsMaleProstate

Identifiers

PMID37988640
PMCPMC10681553
OpenAlexW4388852942

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.